Daraxonrasib, developed to treat advanced forms of the disease, nearly doubled median overall survival compared to standard chemotherapy in patients with metastatic pancreatic cancer, according to clinical trial data presented at the American Society of Clinical Oncology Annual Meeting. The drug, which operates as a targeted therapy against RAS proteins, marks a notable shift in treating a cancer long considered resistant to conventional therapies.
Clinical Trial Results and Survival Metrics
Participants in the Phase 3 clinical trial known as RASolute 302 who received daraxonrasib achieved a median overall survival time of approximately 13.2 months. By comparison, patients treated with standard chemotherapy recorded a median survival of about 6.7 months. Rachna Shroff, a pancreatic cancer expert at the University of Arizona Cancer Center, described the survival figures as unprecedented for advanced pancreatic cancer cases involving patients who had already undergone prior treatment.
Mechanism of Action Targeting RAS Proteins
Daraxonrasib functions as a daily pill that targets RAS proteins, which normally regulate cell growth but drive out-of-control cellular proliferation when abnormally activated. Approximately 90% of pancreatic cancers link directly to changes in RAS, alongside multiple lung and colorectal cancers. For decades, drug developers struggled to target the pathway due to the smooth surface of RAS proteins, which historically offered no anchor point for medicines. Daraxonrasib overcomes this structural hurdle by acting as a molecular glue that binds a helper protein to form a surface capable of locking onto and blocking RAS growth signals.
Side Effect Profile and Patient Tolerability
In addition to extending survival, patients taking daraxonrasib experienced more manageable side effects than those receiving conventional chemotherapy. Because traditional chemotherapy destroys both healthy and cancerous cells simultaneously, it often produces severe toxicity. Targeted therapies isolate cancer cells more specifically, resulting in side effects primarily limited to manageable rashes and mouth sores during trial phases.
Regulatory Status and Future Outlook
The U.S. Food and Drug Administration approved daraxonrasib on August 26, 2026, for adults with metastatic pancreatic cancer who have received at least one prior treatment, with the medication made available under the brand name Rasonque. Researchers continue to evaluate the therapy in additional clinical trials to determine its broader efficacy across other RAS-driven malignancies, including specific forms of lung and colorectal cancer.